1
|
Haktanır D, Yılmaz S. Sexual Dysfunction and Related Factors in Patients With Parkinson's Disease. J Psychosoc Nurs Ment Health Serv 2023; 61:45-55. [PMID: 36099483 DOI: 10.3928/02793695-20220907-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The current cross-sectional study investigated sexual dysfunction and related factors in patients with Parkinson's disease (PD). The sample comprised 76 patients with PD in the neurology clinic of a training and research hospital. Data were collected using the Hospital Anxiety and Depression Scale and Arizona Sexual Experiences Scale. Approximately nine (88.2%) in 10 participants had sexual dysfunction. Sexual dysfunction depended on sex, educational background, employment status, side effects, body image, difficulty falling asleep, self-care, and walking dependence. Sexual dysfunction was positively correlated with age and symptoms of depression and anxiety. Sexual dysfunction was more prevalent in females than males. Advanced age and high risk of depression resulted in increased prevalence of sexual dysfunction. Health care professionals should evaluate the causes of sexual dysfunction and plan and implement appropriate interventions for patients with PD. [Journal of Psychosocial Nursing and Mental Health Services, 61(3), 45-55.].
Collapse
|
2
|
Gamborg M, Hvid LG, Dalgas U, Langeskov‐Christensen M. Parkinson's disease and intensive exercise therapy - An updated systematic review and meta-analysis. Acta Neurol Scand 2022; 145:504-528. [PMID: 34997759 DOI: 10.1111/ane.13579] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 12/08/2021] [Accepted: 12/21/2021] [Indexed: 01/01/2023]
Abstract
In 2015, Uhrbrand et al. published the first review on Parkinson´s disease (PD) and exercise entirely based on randomized controlled trials (RCT) applying strict exercise definitions. The present review aimed to update the PD literature by assessing the effects of different intensive exercise modalities: resistance training (RT), endurance training (ET), and other intensive exercise modalities (OITM). An updated systematic literature search identified 33 new RCTs. Qualitative and quantitative analyses were performed. A total of 18 RT, 14 ET, and 1 OITM studies were identified (adding to the 8 RT, 6 ET, and 4 OITM studies identified by Uhrbrand et al. in 2015). RT, ET, and OITM were feasible, safe, and did not worsen PD symptoms. Furthermore, RT, ET, and OITM may positively affect functional outcomes (e.g., balance) and depressive symptoms in PD but inconsistencies across these findings warrant cautious conclusions. Meta-analyses showed that RT had a positive impact on muscle strength (standardized mean difference (SMD) = 0.83 [95% CI;0.54, 1.12]), functional capacity (Timed Up and Go Test (TUG): SMD = -0.62 [-1.01, -0.24]), and quality of life (SMD = -0.41 [-0.72, -0.09]), while ET had a positive impact on cardiorespiratory fitness (SMD = 0.27 [0.07, 0.47]) and functional capacity (TUG: SMD = -0.21 [-0.46, 0.04], 6-Min Walk Test: SMD = 0.89 [0.17, 1.62]), and a potentially positive impact on "on-medication" UPDRS-III (SMD = -0.15 [-0.38, 0.09]) and "off-medication" UPDRS-III (SMD = -0.19 [-0.41, 0.04]). In conclusion, RT, ET, and OITM all represent safe, feasible, and beneficial adjunct rehabilitation strategies in PD, with particularly RT and ET showing solid effects.
Collapse
Affiliation(s)
- Mads Gamborg
- Exercise Biology Department of Public Health Aarhus University Aarhus Denmark
| | - Lars G. Hvid
- Exercise Biology Department of Public Health Aarhus University Aarhus Denmark
- The Danish MS Hospitals, Ry and Haslev Denmark
| | - Ulrik Dalgas
- Exercise Biology Department of Public Health Aarhus University Aarhus Denmark
| | | |
Collapse
|
3
|
Cysteine Donor-Based Brain-Targeting Prodrug: Opportunities and Challenges. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2022; 2022:4834117. [PMID: 35251474 PMCID: PMC8894025 DOI: 10.1155/2022/4834117] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 02/11/2022] [Indexed: 12/20/2022]
Abstract
Overcoming blood-brain barrier (BBB) to improve brain bioavailability of therapeutic drug remains an ongoing concern. Prodrug is one of the most reliable approaches for delivering agents with low-level BBB permeability into the brain. The well-known antioxidant capacities of cysteine (Cys) and its vital role in glutathione (GSH) synthesis indicate that Cys-based prodrug could potentiate therapeutic drugs against oxidative stress-related neurodegenerative disorders. Moreover, prodrug with Cys moiety could be recognized by the excitatory amino acid transporter 3 (EAAT3) that is highly expressed at the BBB and transports drug into the brain. In this review, we summarized the strategies of crossing BBB, properties of EAAT3 and its natural substrates, Cys and its donors, and Cys donor-based brain-targeting prodrugs by referring to recent investigations. Moreover, the challenges that we are faced with and future research orientations were also addressed and proposed. It is hoped that present review will provide evidence for the pursuit of novel Cys donor-based brain-targeting prodrug.
Collapse
|
4
|
Lavrova AV, Gretskaya NM, Bezuglov VV. Role of Oxidative Stress in the Etiology of Parkinson’s Disease: Advanced Therapeutic Products. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2021. [DOI: 10.1134/s1068162021050307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
5
|
Duncan D. Role of the community nurse in Parkinson's disease and lower urinary disorders. Br J Community Nurs 2021; 26:251-254. [PMID: 33939461 DOI: 10.12968/bjcn.2021.26.5.251] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Parkinson's disease (PD) is an incurable and progressive neurodegenerative disorder. People with PD also have increased muscle weakness and the typical symptoms of tremor, stiffness, slowness, balance problems and/or gait disorders. Other symptoms may include an overactive bladder, urgency and nocturia which can often lead to incontinence. Treatment options vary are dependent on the cause of the incontinence and should focus on improving Quality of life with a multi-pronged diagnosis-specific approach that takes into consideration a patient's ability to comply with treatment. The article looks at the role of the community nurse in caring for patients with PD and lower urinary disorders. They have a key role in assessment of patients and supporting families with tailor made bladder training such as establish a regular toilet routine, education about pelvic floor exercises or supply of incontinence products.
Collapse
Affiliation(s)
- Debbie Duncan
- Lecturer (Education), School of Nursing and Midwifery, Queen's University, Belfast
| |
Collapse
|
6
|
Abraham ME, Gold J, Dondapati A, Gendreau J, Mammis A, Herschman Y. Intrathecal and intracerebroventricular dopamine for Parkinson's disease. Clin Neurol Neurosurg 2020; 200:106374. [PMID: 33290887 DOI: 10.1016/j.clineuro.2020.106374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 10/12/2020] [Accepted: 11/14/2020] [Indexed: 10/22/2022]
Abstract
While CDD directly to the CSF can provide a constant delivery of the dopaminergic drug resulting in a more stable treatment effect without the limitations of traditional oral therapy without peripheral effects, it is still young and longitudinal data is lacking. These experimental therapies show promise and further investigation into their efficacy and safety could extend the frontiers for management of PD.
Collapse
Affiliation(s)
- Mickey E Abraham
- Department of Neurological Surgery, Doctor's Office Center, Rutgers New Jersey Medical School, 90 Bergen Street, 07101-1709, Newark, NJ, United States
| | - Justin Gold
- Department of Neurological Surgery, Doctor's Office Center, Rutgers New Jersey Medical School, 90 Bergen Street, 07101-1709, Newark, NJ, United States.
| | - Akhil Dondapati
- Department of Neurological Surgery, Doctor's Office Center, Rutgers New Jersey Medical School, 90 Bergen Street, 07101-1709, Newark, NJ, United States
| | - Julian Gendreau
- Department of Neurological Surgery, Doctor's Office Center, Rutgers New Jersey Medical School, 90 Bergen Street, 07101-1709, Newark, NJ, United States
| | - Antonios Mammis
- Department of Neurological Surgery, Doctor's Office Center, Rutgers New Jersey Medical School, 90 Bergen Street, 07101-1709, Newark, NJ, United States
| | - Yehuda Herschman
- Department of Neurological Surgery, Doctor's Office Center, Rutgers New Jersey Medical School, 90 Bergen Street, 07101-1709, Newark, NJ, United States
| |
Collapse
|
7
|
Barnish MS, Barran SM. A systematic review of active group-based dance, singing, music therapy and theatrical interventions for quality of life, functional communication, speech, motor function and cognitive status in people with Parkinson's disease. BMC Neurol 2020; 20:371. [PMID: 33038925 PMCID: PMC7547481 DOI: 10.1186/s12883-020-01938-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 09/23/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Parkinson's disease (PD) is a common neurodegenerative condition associated with a wide range of motor and non-motor symptoms. There has been increasing interest in the potential benefit of performing arts as a therapeutic medium in PD. While there have been previous reviews, none have considered all performing arts modalities and most have focused on dance. This systematic review examined the potential benefit of all active group-based performing arts interventions for quality of life, functional communication, speech, motor function and cognitive status. METHODS Searches were conducted in February 2020 on five scholarly databases. Supplementary searches were conducted. Included studies were quantitative in design, and assessed the potential benefit of any active group-based performing arts intervention for quality of life, functional communication, speech, motor function or cognitive status in people with PD. Full text papers were eligible for inclusion, as were conference abstracts since January 2018. Screening, data extraction, narrative synthesis and quality assessment were conducted independently by two reviewers. Quality assessment used the SURE checklists. RESULTS Fifty-six studies were eligible for inclusion in this systematic review, reported in 67 publications. Published from 1989 to 2020, these studies included a total of 1531 people with PD from 12 countries, and covered four broad performing arts modalities: dance, singing, music therapy and theatre. Dance remains the most commonly studied performing arts modality for PD (38 studies), while there were 12 studies on singing interventions, four on music therapy, and only two on theatrical interventions. There was evidence for a beneficial effect of all four performing arts modalities on at least some outcome domains. CONCLUSIONS This is the first systematic review to assess the potential benefit of all active group-based performing arts interventions in PD. The evidence suggests that performing arts may be a useful therapeutic medium in PD. However, a substantial limitation of the evidence base is that no studies compared interventions from different performing arts modalities. Moreover, not all performing arts modalities were assessed for all outcome domains. Therefore it is not currently possible to determine which performing arts modalities are most beneficial for which specific outcomes.
Collapse
Affiliation(s)
- Maxwell S. Barnish
- Peninsula Technology Assessment Group (PenTAG), Institute of Health Research, University of Exeter Medical School, Exeter, UK
- Evidence Synthesis and Modelling for Health Improvement (ESMI), University of Exeter Medical School, Exeter, UK
| | - Susannah M. Barran
- Children and Young People’s Speech and Language Therapy, Evelina London Community Children’s Services, Mary Sheridan Health Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
| |
Collapse
|
8
|
Orozco-Arroyave JR, Vásquez-Correa JC, Klumpp P, Pérez-Toro PA, Escobar-Grisales D, Roth N, Ríos-Urrego CD, Strauss M, Carvajal-Castaño HA, Bayerl S, Castrillón-Osorio LR, Arias-Vergara T, Künderle A, López-Pabón FO, Parra-Gallego LF, Eskofier B, Gómez-Gómez LF, Schuster M, Nöth E. Apkinson: the smartphone application for telemonitoring Parkinson's patients through speech, gait and hands movement. Neurodegener Dis Manag 2020; 10:137-157. [PMID: 32571150 DOI: 10.2217/nmt-2019-0037] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: This paper introduces Apkinson, a mobile application for motor evaluation and monitoring of Parkinson's disease patients. Materials & methods: The App is based on previously reported methods, for instance, the evaluation of articulation and pronunciation in speech, regularity and freezing of gait in walking, and tapping accuracy in hand movement. Results: Preliminary experiments indicate that most of the measurements are suitable to discriminate patients and controls. Significance is evaluated through statistical tests. Conclusion: Although the reported results correspond to preliminary experiments, we think that Apkinson is a very useful App that can help patients, caregivers and clinicians, in performing a more accurate monitoring of the disease progression. Additionally, the mobile App can be a personal health assistant.
Collapse
Affiliation(s)
- Juan Rafael Orozco-Arroyave
- GITA Research Lab, Faculty of Engineering, University of Antioquia, 050010 Medellín-Colombia.,LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany
| | - Juan Camilo Vásquez-Correa
- GITA Research Lab, Faculty of Engineering, University of Antioquia, 050010 Medellín-Colombia.,LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany
| | - Philipp Klumpp
- LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany
| | - Paula Andrea Pérez-Toro
- GITA Research Lab, Faculty of Engineering, University of Antioquia, 050010 Medellín-Colombia
| | - Daniel Escobar-Grisales
- GITA Research Lab, Faculty of Engineering, University of Antioquia, 050010 Medellín-Colombia
| | - Nils Roth
- MaD Lab, Faculty of Engineering, University or Erlangen, 91052 Erlangen-Germany
| | | | - Martin Strauss
- LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany
| | | | - Sebastian Bayerl
- LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany
| | | | - Tomas Arias-Vergara
- GITA Research Lab, Faculty of Engineering, University of Antioquia, 050010 Medellín-Colombia.,LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany.,Department of Otorhinolaryngology, Head & Neck Surgery, Ludwig-Maximilians University, 81377 Munich-Germany
| | - Arne Künderle
- MaD Lab, Faculty of Engineering, University or Erlangen, 91052 Erlangen-Germany
| | | | | | - Björn Eskofier
- MaD Lab, Faculty of Engineering, University or Erlangen, 91052 Erlangen-Germany
| | - Luis Felipe Gómez-Gómez
- GITA Research Lab, Faculty of Engineering, University of Antioquia, 050010 Medellín-Colombia
| | - Maria Schuster
- Department of Otorhinolaryngology, Head & Neck Surgery, Ludwig-Maximilians University, 81377 Munich-Germany
| | - Elmar Nöth
- LME Lab, Faculty of Engineering, University of Erlangen, 91058 Erlangen-Germany
| |
Collapse
|
9
|
Clael S, Bezerra L. Strength and physical functions in people with Parkinson's disease. FUTURE NEUROLOGY 2019. [DOI: 10.2217/fnl-2019-0009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Sacha Clael
- Faculty of Physical Education, University of Brasília, Brasília, Brazil
- Mauá Institute of Research & Education, Brasília, Brazil
- Integrated College IESGO, Formosa, Goiânia
| | - Lídia Bezerra
- Faculty of Physical Education, University of Brasília, Brasília, Brazil
| |
Collapse
|
10
|
Hamed MA, Mohammed MA, Aboul Naser AF, Matloub AA, Fayed DB, Ali SA, Khalil WK. Optimization of Curcuminoids Extraction for Evaluation Against Parkinson’s Disease in Rats. JOURNAL OF BIOLOGICALLY ACTIVE PRODUCTS FROM NATURE 2019. [DOI: 10.1080/22311866.2019.1698317] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Manal A. Hamed
- Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza, Egypt
| | - Mona A. Mohammed
- Medicinal and Aromatic Plants Research Department, National Research Centre, Dokki, Giza, Egypt
| | - Asmaa F. Aboul Naser
- Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza, Egypt
| | - Azaa A. Matloub
- Pharmacognosy Department, National Research Centre, Dokki, Giza, Egypt
| | - Dalia B. Fayed
- Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza, Egypt
| | - Sanaa A. Ali
- Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza, Egypt
| | - Wagdy K.B. Khalil
- Cell Biology Department, National Research Centre, Dokki, Giza, Egypt
| |
Collapse
|
11
|
Kalaani J, Roche J, Hamade E, Badran B, Jaber M, Gaillard A, Prestoz L. Axon guidance molecule expression after cell therapy in a mouse model of Parkinson's disease. Restor Neurol Neurosci 2018; 34:877-895. [PMID: 27858721 DOI: 10.3233/rnn-150587] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND Cell therapy is a promising approach for Parkinson's disease (PD). Others and we have previously shown that transplantation of ventral mesencephalic fetal cells into substantia nigra (SN) in an animal model of PD enables anatomical and functional repair of the degenerated pathway. However, the molecular basis of this repair is still largely unknown. OBJECTIVE In this work, we studied the expression of several axon guidance molecules that may be implicated in the repair of the degenerated nigrostriatal pathway. METHODS The expression of axon guidance molecules was analyzed using qRT-PCR on five specific regions surrounding the nigrostriatal pathway (ventral mesencephalon (VM), thalamus (Thal), medial forebrain bundle (MFB), nucleus accumbens (NAcc) and caudate putamen (CPu)), one and seven days after lesion and transplantation. RESULTS We showed that mRNA expression of specific axon guidance molecules and their receptors is modified in structures surrounding the nigrostriatal pathway, suggesting their involvement in the axon guidance of grafted neurons. Moreover, we highlight a possible new role for semaphorin 7A in this repair. CONCLUSION Overall, our data provide a reliable basis to understand how axons of grafted neurons are able to navigate towards their targets and interact with the molecular environment in the adult brain. This should help to improve the efficiency of cell replacement approaches in PD.
Collapse
Affiliation(s)
- Joanna Kalaani
- Université de Poitiers, INSERM U-1084, Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC), Poitiers, France
| | - Joëlle Roche
- Université de Poitiers, INSERM U-1084, Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC), Poitiers, France
| | - Eva Hamade
- Doctoral School of Sciences and Technology (DSST-PRASE), Lebanese University, Hadath, Lebanon
| | - Bassam Badran
- Doctoral School of Sciences and Technology (DSST-PRASE), Lebanese University, Hadath, Lebanon
| | - Mohamed Jaber
- Université de Poitiers, INSERM U-1084, Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC), Poitiers, France.,CHU de Poitiers, Poitiers, France
| | - Afsaneh Gaillard
- Université de Poitiers, INSERM U-1084, Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC), Poitiers, France
| | - Laetitia Prestoz
- Université de Poitiers, INSERM U-1084, Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC), Poitiers, France
| |
Collapse
|
12
|
Barnish J, Atkinson RA, Barran SM, Barnish MS. Potential Benefit of Singing for People with Parkinson's Disease: A Systematic Review. JOURNAL OF PARKINSONS DISEASE 2017; 6:473-84. [PMID: 27258698 DOI: 10.3233/jpd-160837] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND There is evidence that participation in performing arts brings psychosocial benefits in the general population and in recent years there has been substantial interest in the potential therapeutic benefit of performing arts, including singing, for people with chronic medical conditions including those of neurological aetiology. OBJECTIVE To systematically review the existing body of evidence regarding the potential benefit of singing on clinical outcomes of people with PD. METHODS Seven online bibliographic databases were systematically searched in January 2016 and supplementary searches were conducted. Full-text original peer-reviewed scientific papers that investigated the potential benefit of singing on at least one of speech, functional communication, cognitive status, motor function and quality of life in human participants with PD were eligible for inclusion. RESULTS 449 unique records were identified, 25 full-text articles were screened and seven studies included in the review. All seven studies assessed the impact of singing on speech, five found partial evidence of benefit and two found no evidence of benefit. One study assessed each of functional communication and quality of life and no significant benefit was found. No included study assessed the impact of singing on motor function or cognitive status. CONCLUSIONS Singing may benefit the speech of people with PD, although evidence is not unequivocal. Further research is required to assess wider benefits including on functional communication, cognitive status, motor function and quality of life. Substantial methodological limitations were identified in the existing literature. Recommendations are made for advancing the state of the literature.
Collapse
Affiliation(s)
| | - Rachel A Atkinson
- Adult Speech and Language Therapy Department, St Helier Hospital, Epsom and St Helier University Hospitals NHS Trust, London, UK
| | - Susannah M Barran
- Children and Young People's Speech and Language Therapy, Evelina London Community Children's Services, Mary Sheridan Health Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Maxwell S Barnish
- Respiratory Research Group, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
| |
Collapse
|
13
|
Barnish MS, Horton SMC, Butterfint ZR, Clark AB, Atkinson RA, Deane KHO. Speech and communication in Parkinson's disease: a cross-sectional exploratory study in the UK. BMJ Open 2017; 7:e014642. [PMID: 28554918 PMCID: PMC5730006 DOI: 10.1136/bmjopen-2016-014642] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVE To assess associations between cognitive status, intelligibility, acoustics and functional communication in PD. DESIGN Cross-sectional exploratory study of functional communication, including a within-participants experimental design for listener assessment. SETTING A major academic medical centre in the East of England, UK. PARTICIPANTS Questionnaire data were assessed for 45 people with Parkinson's disease (PD), who had self-reported speech or communication difficulties and did not have clinical dementia. Acoustic and listener analyses were conducted on read and conversational speech for 20 people with PD and 20 familiar conversation partner controls without speech, language or cognitive difficulties. MAIN OUTCOME MEASURES Functional communication assessed by the Communicative Participation Item Bank (CPIB) and Communicative Effectiveness Survey (CES). RESULTS People with PD had lower intelligibility than controls for both the read (mean difference 13.7%, p=0.009) and conversational (mean difference 16.2%, p=0.04) sentences. Intensity and pause were statistically significant predictors of intelligibility in read sentences. Listeners were less accurate identifying the intended emotion in the speech of people with PD (14.8% point difference across conditions, p=0.02) and this was associated with worse speaker cognitive status (16.7% point difference, p=0.04). Cognitive status was a significant predictor of functional communication using CPIB (F=8.99, p=0.005, η2 = 0.15) but not CES. Intelligibility in conversation sentences was a statistically significant predictor of CPIB (F=4.96, p=0.04, η2 = 0.19) and CES (F=13.65, p=0.002, η2 = 0.43). Read sentence intelligibility was not a significant predictor of either outcome. CONCLUSIONS Cognitive status was an important predictor of functional communication-the role of intelligibility was modest and limited to conversational and not read speech. Our results highlight the importance of focusing on functional communication as well as physical speech impairment in speech and language therapy (SLT) for PD. Our results could inform future trials of SLT techniques for PD.
Collapse
Affiliation(s)
- Maxwell S Barnish
- School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
| | - Simon M C Horton
- School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
| | - Zoe R Butterfint
- School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
| | - Allan B Clark
- Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
| | - Rachel A Atkinson
- Adult Speech and Language Therapy Department, St Helier Hospital, Epsom and St Helier University Hospitals NHS Trust, London, UK
| | - Katherine H O Deane
- School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
| |
Collapse
|
14
|
Munoz DA, Kilinc MS, Nembhard HB, Tucker C, Huang X. Evaluating the Cost-Effectiveness of an Early Detection of Parkinson's Disease through Innovative Technology. THE ENGINEERING ECONOMIST 2017; 62:180-196. [PMID: 30135608 PMCID: PMC6101669 DOI: 10.1080/0013791x.2017.1294718] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Early detection of Parkinson's Disease (PD) is critically important as it can increase patient quality of life and save treatment cost. An innovative approach for early detection of PD is to use non-wearable sensors that are capable of capturing skeletal joint data. This paper evaluates the cost-effectiveness of this sensor-based intervention considering the quality-adjusted life years (QALYs) and the associated costs. The results indicate that the intervention would be cost-effective if devices were deployed for community health screening in public places such as health fairs and pharmacies.
Collapse
Affiliation(s)
- David A Munoz
- Department of Industrial and Manufacturing Engineering, The Pennsylvania State University
- Clinical and Translational Science Institute, The Pennsylvania State University
| | - Mehmet Serdar Kilinc
- Department of Industrial and Manufacturing Engineering, The Pennsylvania State University
- Clinical and Translational Science Institute, The Pennsylvania State University
| | - Harriet B Nembhard
- Department of Industrial and Manufacturing Engineering, The Pennsylvania State University
- Clinical and Translational Science Institute, The Pennsylvania State University
| | - Conrad Tucker
- Department of Industrial and Manufacturing Engineering, The Pennsylvania State University
- Department of Engineering Design, The Pennsylvania State University
| | - Xuemei Huang
- College of Medicine, The Pennsylvania State University
| |
Collapse
|
15
|
Ma XW, Guo RY. Dose-dependent effect of Curcuma longa for the treatment of Parkinson's disease. Exp Ther Med 2017; 13:1799-1805. [PMID: 28565770 PMCID: PMC5443238 DOI: 10.3892/etm.2017.4225] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 07/22/2016] [Indexed: 12/26/2022] Open
Abstract
Curcuma longa is a plant that belongs to the ginger family, Zingiberaceae. It has been used in Siddha medicine for thousands of years in Asia. Parkinson's disease (PD) is a degenerative disorder of the central nervous system that affects the motor system of the brain. Death of dopamine-producing cells in the substantia nigra leads to PD. Exposure to salsolinol, which is an endogenous neurotoxin, has been associated with damage to dopamine-producing cells. The present study assessed the toxicity of salsolinol in SH-SY5Y human neuroblastoma cells and subsequently investigated the neuroprotective potential of C. longa extract in salsolinol-induced toxic conditions in SH-SY5Y cells. Sulphorhodamine-B assay showed the protective effect of the anti-apoptotic effect of treated SH-SY5Y cells. Fluorescence microscopy and confocal laser scanning microscope analysis indicated the anti-apoptotic impact of the C. longa extract. Mitochondria-derived reactive oxygen species were reduced in C. longa extract-treated SH-SY5Y cells. Downregulated mRNA expression levels of p53, Bcl-2-associated X protein and caspase 3 were observed in the C. longa extract-treated SH-SY5Y cells. Caspase 3 activity was reduced in the C. longa extract-treated SH-SY5Y cells. In conclusion, the present findings demonstrated that solsolinol is neurotoxic to SH-SY5Y cells, and C. longa extract may be useful in the treatment of PD.
Collapse
Affiliation(s)
- Xiao-Wei Ma
- Department of Neurology, Haici Hospital Affiliated to Medical College of Qingdao University, Qingdao, Shandong 266000, P.R. China
| | - Rui-You Guo
- Department of Neurology, Haici Hospital Affiliated to Medical College of Qingdao University, Qingdao, Shandong 266000, P.R. China
| |
Collapse
|
16
|
Angelucci F, Piermaria J, Gelfo F, Shofany J, Tramontano M, Fiore M, Caltagirone C, Peppe A. The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects. Can J Physiol Pharmacol 2016; 94:455-61. [DOI: 10.1139/cjpp-2015-0322] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Increasing evidence suggests that motor rehabilitation may delay Parkinson’s disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30–T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III – Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.
Collapse
Affiliation(s)
- Francesco Angelucci
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
| | - Jacopo Piermaria
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
| | - Francesca Gelfo
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
- Department of Systemic Medicine, “Tor Vergata” University, Via Montpellier 1, 00133 Rome, Italy
| | - Jacob Shofany
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
| | - Marco Tramontano
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
| | - Marco Fiore
- Institute of Cellular Biology and Neurobiology, CNR, Via del Fosso di Fiorano 64, 00143 Rome, Italy
| | - Carlo Caltagirone
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
- Department of Systemic Medicine, “Tor Vergata” University, Via Montpellier 1, 00133 Rome, Italy
| | - Antonella Peppe
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
| |
Collapse
|
17
|
Xu F, Ma W, Huang Y, Qiu Z, Sun L. Deep brain stimulation of pallidal versus subthalamic for patients with Parkinson's disease: a meta-analysis of controlled clinical trials. Neuropsychiatr Dis Treat 2016; 12:1435-44. [PMID: 27382286 PMCID: PMC4922776 DOI: 10.2147/ndt.s105513] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Parkinson's disease (PD) is a common neurodegenerative disorder that affects many people every year. Deep brain stimulation (DBS) is an effective nonpharmacological method to treat PD motor symptoms. This meta-analysis was conducted to evaluate the efficacy of subthalamic nucleus (STN)-DBS versus globus pallidus internus (GPi)-DBS in treating advanced PD. METHODS Controlled clinical trials that compared STN-DBS to GPi-DBS for short-term treatment of PD in adults were researched up to November 2015. The primary outcomes were the Unified Parkinson's Disease Rating Scale Section (UPDRS) III score and the levodopa-equivalent dosage (LED) after DBS. The secondary outcomes were the UPDRS II score and the Beck Depression Inventory (BDI) score. RESULTS Totally, 13 studies containing 1,148 PD patients were included in this meta-analysis to compare STN-DBS versus GPi-DBS. During the off-medication state, the pooled weighted mean difference (WMD) of UPDRS III and II scores were -2.18 (95% CI =-5.11 to 0.74) and -1.96 (95% CI =-3.84 to -0.08), respectively. During the on-medication state, the pooled WMD of UPDRS III and II scores were 0.15 (95% CI =-1.14 to 1.44) and 1.01 (95% CI =0.12 to 1.89), respectively. After DBS, the pooled WMD of LED and BDI were -254.48 (95% CI =-341.66) and 2.29 (95% CI =0.83 to 3.75), respectively. CONCLUSION These results indicate that during the off-medication state, the STN-DBS might be superior to GPi-DBS in improving the motor function and activities of daily living for PD patients; but during the on-medication state, the opposite result is observed. Meanwhile, the STN-DBS is superior at reducing the LED, whereas the GPi-DBS shows a significantly greater reduction in BDI score after DBS.
Collapse
Affiliation(s)
- Fan Xu
- Interdisciplinary Division of Biomedical Engineering, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, People's Republic of China
| | - Wenbin Ma
- Department of Neurology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China
| | - Yongmin Huang
- Interdisciplinary Division of Biomedical Engineering, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, People's Republic of China
| | - Zhihai Qiu
- Interdisciplinary Division of Biomedical Engineering, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, People's Republic of China
| | - Lei Sun
- Interdisciplinary Division of Biomedical Engineering, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, People's Republic of China
| |
Collapse
|
18
|
Orozco-Arroyave JR, Hönig F, Arias-Londoño JD, Vargas-Bonilla JF, Daqrouq K, Skodda S, Rusz J, Nöth E. Automatic detection of Parkinson's disease in running speech spoken in three different languages. THE JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA 2016; 139:481-500. [PMID: 26827042 DOI: 10.1121/1.4939739] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
The aim of this study is the analysis of continuous speech signals of people with Parkinson's disease (PD) considering recordings in different languages (Spanish, German, and Czech). A method for the characterization of the speech signals, based on the automatic segmentation of utterances into voiced and unvoiced frames, is addressed here. The energy content of the unvoiced sounds is modeled using 12 Mel-frequency cepstral coefficients and 25 bands scaled according to the Bark scale. Four speech tasks comprising isolated words, rapid repetition of the syllables /pa/-/ta/-/ka/, sentences, and read texts are evaluated. The method proves to be more accurate than classical approaches in the automatic classification of speech of people with PD and healthy controls. The accuracies range from 85% to 99% depending on the language and the speech task. Cross-language experiments are also performed confirming the robustness and generalization capability of the method, with accuracies ranging from 60% to 99%. This work comprises a step forward for the development of computer aided tools for the automatic assessment of dysarthric speech signals in multiple languages.
Collapse
Affiliation(s)
- J R Orozco-Arroyave
- Faculty of Engineering, Universidad de Antioquia, Calle 67 Número 53-108, Medellín 1226, Colombia
| | - F Hönig
- Pattern Recognition Lab, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Martensstraβe 3, Erlangen 91058, Germany
| | - J D Arias-Londoño
- Faculty of Engineering, Universidad de Antioquia, Calle 67 Número 53-108, Medellín 1226, Colombia
| | - J F Vargas-Bonilla
- Faculty of Engineering, Universidad de Antioquia, Calle 67 Número 53-108, Medellín 1226, Colombia
| | - K Daqrouq
- Department of Electrical and Computer Engineering, King Abdulaziz University, Jeddah 22254, Saudi Arabia
| | - S Skodda
- Department of Neurology, Knappschaftskrankenhaus, Ruhr-University, In der Schornau 23-25, Bochum D-44892, Germany
| | - J Rusz
- Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Technicka 2, 166 27 Prague 6, Czech Republic
| | - E Nöth
- Pattern Recognition Lab, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Martensstraβe 3, Erlangen 91058, Germany
| |
Collapse
|
19
|
Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease. PARKINSON'S DISEASE 2015; 2015:931058. [PMID: 26664824 PMCID: PMC4667061 DOI: 10.1155/2015/931058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 10/13/2015] [Accepted: 10/20/2015] [Indexed: 02/04/2023]
Abstract
Aim. In this study we examined the influence of tetrandrine (Tet) on the neuroprotective effects of glutathione (GSH) in the 6-hydroxydopamine- (6-OHDA-) lesioned rat model of Parkinson's disease (PD). Methods. Levels in the redox system, dopamine (DA) metabolism, dopaminergic neuronal survival, and apoptosis of the substantia nigra (SN) and striatum, as well as the rotational behavior of animals were examined after a 50-day administration of GSH + Tet (or GSH) and/or L-3,4-dihydroxyphenylalanine (L-dopa) to PD rats. Ethics Committee of Huashan Hospital, Fudan University approved the protocol (number SYXK2009-0082). Results. Administration of GSH or Tet alone did not show any significant effects on the factors evaluated in the PD rats. However, in the GSH + Tet group, we observed markedly decreased oxidative damage, inhibition of DA metabolism and enhanced DA synthesis, increased tyrosine hydroxylase- (TH-) immunopositive neuronal survival, and delayed apoptosis of dopaminergic neurons in the SN. Animal rotational behavior was improved in the GSH + Tet group. Additionally, coadministration of GSH + Tet appeared to offset the possible oxidative neurotoxicity induced by L-dopa. Conclusion. In this study, we demonstrated that tetrandrine allowed occurrence of the neuroprotective effect of glutathione probably due to inhibition of P-glycoprotein on 6-hydroxydopamine-lesioned rat models of Parkinson's disease, including rats undergoing long-term L-dopa treatment.
Collapse
|
20
|
|
21
|
Uhrbrand A, Stenager E, Pedersen MS, Dalgas U. Parkinson's disease and intensive exercise therapy--a systematic review and meta-analysis of randomized controlled trials. J Neurol Sci 2015; 353:9-19. [PMID: 25936252 DOI: 10.1016/j.jns.2015.04.004] [Citation(s) in RCA: 127] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Revised: 03/17/2015] [Accepted: 04/02/2015] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To evaluate and compare the effect of 3 intensive exercise therapy modalities - Resistance Training (RT), Endurance Training (ET) and Other Intensive Training Modalities (OITM) - in Parkinson's Disease (PD). Design A systematic review and meta-analysis of randomized controlled trials. METHODS A systematic literature search was conducted (Embase, Pubmed, Cinahl, SPORTDiscus, Cochrane, PEDro), which identified 15 studies that were categorized as RT, ET or OITM. The different exercise modalities were reviewed and a meta-analysis evaluating the effect of RT on muscle strength was made. RESULTS In PD intensive exercise therapy (RT, ET and OITM) is feasible and safe. There is strong evidence that RT can improve muscle strength in PD, which is underlined by the meta-analysis (g'=0.54 [95%CI 0.22;0.86]). There is moderate evidence that ET can improve cardio-respiratory fitness in PD. RT, ET and OITM may have beneficial effects on balance, walking performance, Unified Parkinson's Disease Rating Scale-III (UPDRS-III) score and quality of life in PD, but findings are inconsistent. No studies find deterioration in any outcomes following exercise therapy. CONCLUSION RT, ET and OITM all represent feasible, safe and beneficial adjunct rehabilitation therapies in PD.
Collapse
Affiliation(s)
- Anders Uhrbrand
- Section of Sport Science, Dep. Public Health, Aarhus University, Denmark.
| | - Egon Stenager
- Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; Department of Neurology & MS-Clinic of Southern Jutland (Sønderborg, Esbjerg, Vejle), Sønderborg Hospital, Denmark
| | | | - Ulrik Dalgas
- Section of Sport Science, Dep. Public Health, Aarhus University, Denmark
| |
Collapse
|
22
|
Gene Therapy for Parkinson’s Disease: AAV5-Mediated Delivery of Glial Cell Line-Derived Neurotrophic Factor (GDNF). NEUROMETHODS 2015. [DOI: 10.1007/978-1-4939-2306-9_3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
|
23
|
Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms. Arch Pharm Res 2014; 38:139-70. [PMID: 25348867 DOI: 10.1007/s12272-014-0503-5] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 10/14/2014] [Indexed: 12/20/2022]
Abstract
Continuous increases in the incidence of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and brain stroke demand the urgent development of therapeutics. Marine organisms are well-known producers of natural products with diverse structures and pharmacological activities. Therefore, researchers have endeavored to identify marine natural products with neuroprotective effects. In this regard, this review summarizes therapeutic targets for AD, PD, and ischemic brain stroke and marine natural products with pharmacological activities on the targets according to taxonomies of marine organisms. Furthermore, several marine natural products on the clinical trials for the treatment of neurological disorders are discussed.
Collapse
|
24
|
Castelli L, Tonello D, Rizzi L, Zibetti M, Lanotte M, Lopiano L. Alexithymia in patients with Parkinson's disease treated with DBS of the subthalamic nucleus: a case-control study. Front Psychol 2014; 5:1168. [PMID: 25352821 PMCID: PMC4195283 DOI: 10.3389/fpsyg.2014.01168] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 09/26/2014] [Indexed: 01/04/2023] Open
Abstract
Objectives: To evaluate the effect of deep brain stimulation of the subthalamic nucleus (STN-DBS) on alexithymia, a deficit in affective regulation, comparing patients with Parkinson’s disease (PD) submitted to STN-DBS (DBS group) to PD patients not yet treated with STN-DBS (pre-DBS group) and to healthy participants (C group). Methods: We recruited 27 consecutive STN-DBS PD patients, 38 consecutive pre-DBS patients and 27 healthy participants. Patients were assessed for alexithymia (Toronto Alexithymia Scale), depression, [beck depression inventory (BDI)], and cognitive functions (reasoning, memory, attentional, and executive tests). Results: The DBS patients performed worse than the pre-DBS patients in the corsi’s block-tapping test, in the phonemic fluency task and in the Frontal Assessment Battery. Around 30% of DBS (29.6%) and pre-DBS (31.6%) patients resulted alexithymic, compared with 14.8% in the C group. The results pointed out significantly higher alexithymia scores in both the DBS and pre-DBS groups compared with the C group, while no difference emerged between the DBS and pre-DBS groups. Pre-DBS group showed a significantly higher BDI score than the C group, while DBS group did not. Conclusion: Although the results suggest that STN-DBS does not affect alexithymia, both the DBS and pre-DBS patients reported higher prevalence (about 30%) of alexithymia than did healthy subjects (14.8%).
Collapse
Affiliation(s)
- Lorys Castelli
- Department of Psychology, University of Turin Turin, Italy
| | - Debora Tonello
- Department of Psychology, University of Turin Turin, Italy
| | - Laura Rizzi
- Department of Neuroscience, University of Turin Turin, Italy
| | | | - Michele Lanotte
- Department of Neuroscience, University of Turin Turin, Italy
| | | |
Collapse
|
25
|
Lökk J, Olofsson S, Persson U. Willingness to pay for a new drug delivery in Parkinson patients. J Multidiscip Healthc 2014; 7:431-40. [PMID: 25336962 PMCID: PMC4199841 DOI: 10.2147/jmdh.s67929] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objective The Swedish reimbursement system operates a system where prices are set based on the expected value to the consumer. This value can be measured using willingness to pay (WTP). Aim To assess Parkinson’s disease (PD) patients’ WTP for newly developed microtablets of levodopa in combination with a drug-delivering electronic device (M/E) compared to standard treatment with levodopa in combination with the COMT (catechol-O-methyl transferase)-inhibitor entacapone (L/e). Method A total of 2,000 randomly included PD patients had a postal questionnaire covering demographics, disease-specific issues, views on medication and WTP in different hypothetical scenarios. The first scenario was M/E with no change in effects or side effects; the second scenario was M/E with same effect and less side effects; and the third scenario was M/E with improved effect and less side effects. These scenarios were coupled to different costs to choose from. Results A total of 999 patients (50%) responded, mean age of 71 years and a mean PD duration of 9 years. Of all respondents, 50% preferred M/E before L/e in scenario one with increasing preference to scenario three. The average monthly WTP among all respondents in scenario one was SEK 230 and SEK 226 in L/e, both with an almost longitudinal doubling up to scenario three. Duration of PD-related symptoms, high education, and high medication intake implied a higher WTP in all scenarios in contrast to age, sex, and extra doses of levodopa. Conclusion WTP for M/E increased gradually with high medication intake and education as well as with expected increased reduction of PD symptoms.
Collapse
Affiliation(s)
- Johan Lökk
- Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden ; Geriatric Department, Karolinska University Hospital, Stockholm, Sweden
| | - Sara Olofsson
- The Swedish Institute for Health Economics, Institute for Health Economics (IHE), Lund, Sweden
| | - Ulf Persson
- The Swedish Institute for Health Economics, Institute for Health Economics (IHE), Lund, Sweden
| |
Collapse
|
26
|
Qualls Z, Brown D, Ramlochansingh C, Hurley LL, Tizabi Y. Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease. Neurotox Res 2014; 25:81-9. [PMID: 24122264 DOI: 10.1007/s12640-013-9433-0] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 09/29/2013] [Accepted: 09/30/2013] [Indexed: 12/21/2022]
Abstract
Parkinson's disease (PD) is a debilitating neurodegenerative disorder that results from the loss of or damage to dopaminergic cells in the substantia nigra. Exposure to either the pesticide rotenone or the endogenous neurotoxin salsolinol has been shown to mimic this dopaminergic cell loss. In this study, we first sought to determine whether combination of rotenone and salsolinol would result in an additive or synergistic toxicity. For this purpose we utilized SH-SY5Y cells, a human neuroblastoma cell line that is commonly used to model dopaminergic neurodegeneration. We then tested whether curcumin, a natural plant compound with known health benefits including potential neuroprotective properties, could also protect against rotenone and/or salsolinol-induced toxicity. Moreover, since apoptotic mechanism has been implicated in toxicity of these compounds the anti-apoptotic effect of curcumin was also evaluated. Our results indicate a synergistic toxicity of low concentrations of rotenone (1 and 5 µM) and salsolinol (25 and 50 µM) that was associated with apoptosis as determined by cell flow cytometry. There was also an increase in caspase-3 levels. Pretreatment with curcumin (1-µM) dose-dependently attenuated rotenone and/or salsolinol-induced toxicity and the associated apoptosis. These results suggest that exposure to a combination of rotenone and salsolinol may contribute to the pathology of PD, and that curcumin has a therapeutic potential in this disease.
Collapse
|
27
|
Vogt I, Prinz J, Campillos M. Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs. Genome Med 2014; 6:52. [PMID: 25276232 PMCID: PMC4165361 DOI: 10.1186/s13073-014-0052-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2014] [Accepted: 07/07/2014] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND The incomplete understanding of disease causes and drug mechanisms of action often leads to ineffective drug therapies or side effects. Therefore, new approaches are needed to improve treatment decisions and to elucidate molecular mechanisms underlying pathologies and unwanted drug effects. METHODS We present here the first analysis of phenotypically related drug-disease pairs. The phenotypic similarity between 4,869 human diseases and 1,667 drugs was evaluated using an ontology-based semantic similarity approach to compare disease symptoms with drug side effects. We assessed and visualized the enrichment over random of clinical and molecular relationships among drug-disease pairs that share phenotypes using lift plots. To determine the associations between drug and disease classes enriched among phenotypically related pairs we employed a network-based approach combined with Fisher's exact test. RESULTS We observed that molecularly and clinically related (for example, indication or contraindication) drugs and diseases are likely to share phenotypes. An analysis of the relations between drug mechanisms of action (MoAs) and disease classes among highly similar pairs revealed known and suspected MoA-disease relationships. Interestingly, we found that contraindications associated with high phenotypic similarity often involve diseases that have been reported as side effects of the drug, probably due to common mechanisms. Based on this, we propose a list of 752 precautions or potential contraindications for 486 drugs. CONCLUSIONS Phenotypic similarity between drugs and diseases facilitates the proposal of contraindications and the mechanistic understanding of diseases and drug side effects.
Collapse
Affiliation(s)
- Ingo Vogt
- />Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- />German Center for Diabetes Research, 85764 Neuherberg, Germany
| | - Jeanette Prinz
- />Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- />German Center for Diabetes Research, 85764 Neuherberg, Germany
| | - Mónica Campillos
- />Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- />German Center for Diabetes Research, 85764 Neuherberg, Germany
| |
Collapse
|
28
|
PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53:35-44. [PMID: 24593945 DOI: 10.1016/j.pnpbp.2014.02.009] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Revised: 02/18/2014] [Accepted: 02/21/2014] [Indexed: 01/23/2023]
Abstract
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The etiology and pathogenesis of PD are still unknown, however, many evidences suggest a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteosomal dysfunction. The peroxisome proliferator-activated receptor (PPAR) ligands, a member of the nuclear receptor family, have anti-inflammatory activity over a variety of rodent's models for acute and chronic inflammation. PPAR-α agonists, a subtype of the PPAR receptors, such as fenofibrate, have been shown a major role in the regulation of inflammatory processes. Animal models of PD have shown that neuroinflammation is one of the most important mechanisms involved in dopaminergic cell death. In addition, anti-inflammatory drugs are able to attenuate toxin-induced parkinsonism. In this study we evaluated the effects of oral administration of fenofibrate 100mg/kg 1h after infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the SNpc. First, we assessed the motor behavior in the open field for 24h, 7, 14 and 21 days after MPTP. Twenty-two days after surgery, the animals were tested for two-way active avoidance and forced swimming for evaluation regarding cognitive and depressive parameters, respectively. Twenty-three days after infusion of the toxin, we quantified DA and turnover and evaluated oxidative stress through the measurement of GSH (glutathione peroxidase), SOD (superoxide dismutase) and LOOH (hydroperoxide lipid). The data show that fenofibrate was able to decrease hypolocomotion caused by MPTP 24h after injury, depressive-like behavior 22 days after the toxin infusion, and also protected against decreased level of DA and excessive production of reactive oxygen species (ROS) 23 days after surgery. Thus, fenofibrate has shown a neuroprotective effect in the MPTP model of Parkinson's disease.
Collapse
|
29
|
Li H, Yusufujiang A, Naser S, Zhu Y, Maimaiti M, He X, Bu J, Meng X, Wang M, Li J, Dina B, Yang L, Nayi Z, Dang H, Wang C, Amiti D, Aji A, Yusufu N, Jiao Y, Duan F. Mutation analysis of PARK2 in a Uyghur family with early-onset Parkinson's disease in Xinjiang, China. J Neurol Sci 2014; 342:21-4. [DOI: 10.1016/j.jns.2014.03.044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 03/19/2014] [Accepted: 03/24/2014] [Indexed: 10/25/2022]
|
30
|
Liu Y, Li W, Tan C, Liu X, Wang X, Gui Y, Qin L, Deng F, Hu C, Chen L. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease. J Neurosurg 2014; 121:709-18. [PMID: 24905564 DOI: 10.3171/2014.4.jns131711] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECT Deep brain stimulation (DBS) is the surgical procedure of choice for patients with advanced Parkinson disease (PD). The globus pallidus internus (GPi) and the subthalamic nucleus (STN) are commonly targeted by this procedure. The purpose of this meta-analysis was to compare the efficacy of DBS in each region. METHODS MEDLINE/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library were searched for English-language studies published before April 2013. RESULTS of studies investigating the efficacy and clinical outcomes of DBS of the GPi and STN for PD were analyzed. RESULTS Six eligible trials containing a total of 563 patients were included in the analysis. Deep brain stimulation of the GPi or STN equally improved motor function, measured by the Unified Parkinson's Disease Rating Scale Section III (UPDRSIII) (motor section, for patients in on- and off-medication phases), within 1 year postsurgery. The change score for the on-medication phase was 0.68 (95% CI - 2.12 to 3.47, p > 0.05; 5 studies, 518 patients) and for the off-medication phase was 1.83 (95% CI - 3.12 to 6.77, p > 0.05; 5 studies, 518 patients). The UPDRS Section II (activities of daily living) scores for patients on medication improved equally in both DBS groups (p = 0.97). STN DBS allowed medication dosages to be reduced more than GPi DBS (95% CI 129.27-316.64, p < 0.00001; 5 studies, 540 patients). Psychiatric symptoms, measured by Beck Depression Inventory, 2nd edition scores, showed greater improvement from baseline after GPi DBS than after STN DBS (standardized mean difference -2.28, 95% CI -3.73 to -0.84, p = 0.002; 3 studies, 382 patients). CONCLUSIONS GPi and STN DBS improve motor function and activities of daily living for PD patients. Differences in therapeutic efficacy for PD were not observed between the 2 procedures. STN DBS allowed greater reduction in medication for patients, whereas GPi DBS provided greater relief from psychiatric symptoms. An understanding of other symptomatic aspects of targeting each region and long-term observations on therapeutic effects are needed.
Collapse
Affiliation(s)
- Yi Liu
- Department of Neurology, the Second Affiliated Hospital of Chong Qing Medical University, YuZhong, Chong Qing, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders. Ann Biomed Eng 2014; 42:1573-93. [PMID: 24833254 DOI: 10.1007/s10439-014-1032-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Accepted: 05/07/2014] [Indexed: 12/17/2022]
Abstract
Traditional approaches for neurological rehabilitation of patients affected with movement disorders, such as Parkinson's disease (PD), dystonia, and essential tremor (ET) consist mainly of oral medication, physical therapy, and botulinum toxin injections. Recently, the more invasive method of deep brain stimulation (DBS) showed significant improvement of the physical symptoms associated with these disorders. In the past several years, the adoption of feedback control theory helped DBS protocols to take into account the progressive and dynamic nature of these neurological movement disorders that had largely been ignored so far. As a result, a more efficient and effective management of PD cardinal symptoms has emerged. In this paper, we review closed-loop systems for rehabilitation of movement disorders, focusing on PD, for which several invasive and noninvasive methods have been developed during the last decade, reducing the complications and side effects associated with traditional rehabilitation approaches and paving the way for tailored individual therapeutics. We then present a novel, transformative, noninvasive closed-loop framework based on force neurofeedback and discuss several future developments of closed-loop systems that might bring us closer to individualized solutions for neurological rehabilitation of movement disorders.
Collapse
|
32
|
Ge J, Wu P, Zuo C. The metabolic brain network in patients with Parkinson's disease based on (18)F-FDG PET imaging: evaluation of neuronal injury and regeneration. Neural Regen Res 2014; 9:763-5. [PMID: 25206887 PMCID: PMC4146272 DOI: 10.4103/1673-5374.131586] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/19/2014] [Indexed: 11/17/2022] Open
Affiliation(s)
- Jingjie Ge
- PET Center, Huashan Hospital, Fudan University, Shanghai 200235, China
| | - Ping Wu
- PET Center, Huashan Hospital, Fudan University, Shanghai 200235, China
| | - Chuantao Zuo
- PET Center, Huashan Hospital, Fudan University, Shanghai 200235, China
| |
Collapse
|
33
|
Zhang B, Albaker A, Plouffe B, Lefebvre C, Tiberi M. Constitutive activities and inverse agonism in dopamine receptors. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2014; 70:175-214. [PMID: 24931197 DOI: 10.1016/b978-0-12-417197-8.00007-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The concept of activation in the absence of agonists has been demonstrated for many GPCRs and is now solidified as one of the principal aspects of GPCR signaling. In this chapter, we review how dopamine receptors demonstrate this ability. Although difficult to prove in vivo due to the presence of endogenous dopamine and lack of subtype-selective inverse agonists and "pure" antagonists (neutral ligands), in vitro assays such as measuring intracellular cAMP, [(35)S]GTPγS binding, and [(3)H]thymidine incorporation have uncovered the constitutive activation of D1- and D2-class receptors. Nevertheless, because of limited and inconsistent findings, the existence of constitutive activity for D2-class receptors is currently not well established. Mutagenesis studies have shown that basal signaling, notably by D1-class receptors, is governed by the collective contributions of transmembrane domains and extracellular/intracellular loops, such as the third extracellular loop, the third intracellular loop, and C-terminal tail. Furthermore, constitutive activities of D1-class receptors are subjected to regulation by kinases. Among the dopamine receptor family, the D5 receptor subtype exhibits a higher basal signaling and bears resemblance to constitutively active mutant forms of GPCRs. The presence of its constitutive activity in vivo and its pathophysiological relevance, with a brief mention of other subtypes, are also discussed.
Collapse
Affiliation(s)
- Boyang Zhang
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada
| | - Awatif Albaker
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada
| | - Bianca Plouffe
- Department of Biochemistry, Université de Montréal, Montréal, Québec, Canada; Institut de recherche en immunologie, cancer, Montréal, Québec, Canada
| | - Caroline Lefebvre
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada
| | - Mario Tiberi
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada.
| |
Collapse
|
34
|
van Wegen EEH, Hirsch MA, Huiskamp M, Kwakkel G. Harnessing Cueing Training for Neuroplasticity in Parkinson Disease. TOPICS IN GERIATRIC REHABILITATION 2014. [DOI: 10.1097/tgr.0000000000000005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Chakraborty S, Bornhorst J, Nguyen TT, Aschner M. Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans. Int J Mol Sci 2013; 14:23103-28. [PMID: 24284401 PMCID: PMC3856108 DOI: 10.3390/ijms141123103] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 10/08/2013] [Accepted: 10/16/2013] [Indexed: 12/11/2022] Open
Abstract
Oxidative stress is thought to play a significant role in the development and progression of neurodegenerative diseases. Although it is currently considered a hallmark of such processes, the interweaving of a multitude of signaling cascades hinders complete understanding of the direct role of oxidative stress in neurodegeneration. In addition to its extensive use as an aging model, some researchers have turned to the invertebrate model Caenorhabditis elegans (C. elegans) in order to further investigate molecular mediators that either exacerbate or protect against reactive oxygen species (ROS)-mediated neurodegeneration. Due to their fully characterized genome and short life cycle, rapid generation of C. elegans genetic models can be useful to study upstream markers of oxidative stress within interconnected signaling pathways. This report will focus on the roles of C. elegans homologs for the oxidative stress-associated transcription factor Nrf2, as well as the autosomal recessive, early-onset Parkinson’s disease (PD)-associated proteins Parkin, DJ-1, and PINK1, in neurodegenerative processes.
Collapse
Affiliation(s)
- Sudipta Chakraborty
- Neuroscience Graduate Program, Vanderbilt University Medical Center, Nashville, TN 37232, USA; E-Mail:
- Center in Molecular Toxicology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; E-Mail:
| | - Julia Bornhorst
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; E-Mail:
| | - Thuy T. Nguyen
- Center in Molecular Toxicology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; E-Mail:
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Michael Aschner
- Center in Molecular Toxicology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; E-Mail:
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; E-Mail:
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +1-718-430-2317
| |
Collapse
|
36
|
Jaber M, Benoit-Marand M, Prestoz L, Gaillard A. Cell transplantation in the damaged adult brain. Rev Neurol (Paris) 2013; 169:838-43. [PMID: 24112517 DOI: 10.1016/j.neurol.2013.07.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 07/04/2013] [Accepted: 07/12/2013] [Indexed: 11/16/2022]
Abstract
Parkinson's disease (PD) is the most common movement disorder in Europe, affecting more than two million people between 50 and 70 years of age. The current therapeutic approaches are of symptomatic nature and fail to halt the progressive neurodegenerative course of the disease. The development of innovative and complementary approaches to promote cellular repair may pave the way for disease-modifying therapies which may lead to less suffering for the patients and their families and finally to more cost-effective therapies. To date, cell replacement trials in PD aiming at replacing lost dopamine neurons were mainly focused on placing the transplanted cells within the target site, the striatum, and not within the lesioned site, the substantia nigra (SN). This was based on the misconception that the adult brain constitutes a non-permissive barrier not allowing the outgrowth of long distance axons originating from transplanted embryonic neurons. A growing body of evidence is challenging this concept and proposing instead to place the graft within its ontogenic site. This has been performed in several lesional animal models for various traumatic or neurodegenerative pathologies of the brain. For instance, transplanted neurons within the lesioned motor cortex were shown to be able to send distant and appropriate projections to target areas including the spinal cord. Similarly, in an animal model of PD, mesencephalic embryonic cells transplanted within the lesioned SN send massive projections to the striatum and, to a lesser extent, the frontal cortex and the nucleus accumbens. This has lead to the proposal that homotopic transplantation may be an alternative in cell-based therapies as transplanted neurons can integrate within the host brain, send projections to target areas, restore the damaged circuitry, increase neurotransmitter levels and ameliorate behavior. We will discuss also the potential of replacing embryonic neuronal cells by stem cell derived neurons as the use of embryonic cells is not without an ethical and logistical burden; in this line many have thrived to derive neurons from embryonic stem cells (ESC) in order to use them for cell transplantation. These studies are already yielding important information for future approaches in the field of cell therapies in PD but also in other neurodegenerative disorders where cell transplantation therapy may be considered. While the field of cell replacement therapies has been recently called into question with contrasting results in transplanted PD patients, these new sets of findings are raising new hopes and opening new avenues in this rejuvenated field.
Collapse
Affiliation(s)
- M Jaber
- Inserm U1084, university of Poitiers, building B36, 1, rue Georges-Bonnet, BP 633, 86022 Poitiers cedex, France.
| | | | | | | |
Collapse
|